Global Multiple Sclerosis Treatment Devices Market By Region
Global Multiple Sclerosis Treatment Devices Market By TYPE
By TYPE, the market is segmented into Clinically Isolated Syndrome (CIS), Deep Brain Stimulation (DBS), Functional Electrical Stimulation (FES), Primary Progressive Multiple Sclerosis (PPMS), Relapsing-remitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS), Spinal Cord Stimulation (SCS), and Transcutaneous Electrical Nerve Stimulation (TENS) (2019–2032)
| Label | Clinically Isolated Syndrome (CIS) | Deep Brain Stimulation (DBS) | Functional Electrical Stimulation (FES) | Primary Progressive Multiple Sclerosis (PPMS) | Relapsing-remitting Multiple Sclerosis (RRMS) | Secondary Progressive Multiple Sclerosis (SPMS) | Spinal Cord Stimulation (SCS) | Transcutaneous Electrical Nerve Stimulation (TENS) |
|---|---|---|---|---|---|---|---|---|
| 2019 | 1.8744 USD Million | 5.9613 USD Million | 19.9407 USD Million | 4.2195 USD Million | 27.272 USD Million | 3.2163 USD Million | 9.806 USD Million | 0.8742 USD Million |
| 2020 | 1.7509 USD Million | 5.6114 USD Million | 18.9653 USD Million | 4.0455 USD Million | 25.9125 USD Million | 3.0342 USD Million | 9.31 USD Million | 0.8564 USD Million |
| 2021 | 1.7584 USD Million | 5.6801 USD Million | 19.3971 USD Million | 4.1707 USD Million | 26.4767 USD Million | 3.0781 USD Million | 9.5051 USD Million | 0.9015 USD Million |
| 2022 | 1.7751 USD Million | 5.781 USD Million | 19.9479 USD Million | 4.323 USD Million | 27.2022 USD Million | 3.1396 USD Million | 9.7575 USD Million | 0.9536 USD Million |
| 2023 | 1.8332 USD Million | 6.0313 USD Million | 21.0339 USD Million | 4.5966 USD Million | 28.6542 USD Million | 3.2839 USD Million | 10.2696 USD Million | 1.0332 USD Million |
| 2024 | 1.8656 USD Million | 6.1834 USD Million | 21.7878 USD Million | 4.7964 USD Million | 29.654 USD Million | 3.373 USD Million | 10.6185 USD Million | 1.0993 USD Million |
| 2025 | 1.8996 USD Million | 6.3456 USD Million | 22.5926 USD Million | 5.0102 USD Million | 30.721 USD Million | 3.4681 USD Million | 10.9906 USD Million | 1.1701 USD Million |
| 2026 | 1.9354 USD Million | 6.5197 USD Million | 23.4562 USD Million | 5.2402 USD Million | 31.866 USD Million | 3.5702 USD Million | 11.3895 USD Million | 1.2463 USD Million |
| 2027 | 1.9719 USD Million | 6.7027 USD Million | 24.3691 USD Million | 5.4844 USD Million | 33.0757 USD Million | 3.6777 USD Million | 11.8105 USD Million | 1.3274 USD Million |
| 2028 | 2.0114 USD Million | 6.9028 USD Million | 25.3635 USD Million | 5.7505 USD Million | 34.3936 USD Million | 3.7952 USD Million | 12.2688 USD Million | 1.4156 USD Million |
| 2029 | 2.0536 USD Million | 7.12 USD Million | 26.4412 USD Million | 6.0395 USD Million | 35.8218 USD Million | 3.9228 USD Million | 12.7653 USD Million | 1.5112 USD Million |
| 2030 | 2.0969 USD Million | 7.3498 USD Million | 27.5883 USD Million | 6.3484 USD Million | 37.3414 USD Million | 4.0581 USD Million | 13.2929 USD Million | 1.6138 USD Million |
| 2031 | 2.1423 USD Million | 7.5966 USD Million | 28.8234 USD Million | 6.6822 USD Million | 38.9771 USD Million | 4.2035 USD Million | 13.8603 USD Million | 1.7248 USD Million |
| 2032 | 2.1904 USD Million | 7.8638 USD Million | 30.1625 USD Million | 7.045 USD Million | 40.7501 USD Million | 4.3611 USD Million | 14.4748 USD Million | 1.8455 USD Million |
Data Source: Wantstats Repository
Growth Outlook
- The Global Multiple Sclerosis Treatment Devices Market By TYPE market is on a steady long-term growth path. Segment value stands at roughly USD 85 Million in 2026 and is projected to reach USD 109 Million by 2032 — a gain of about 28% over the forecast period, translating to a CAGR in the mid-single digits.
- What the regional split looks like (2026): Relapsing-remitting Multiple Sclerosis (RRMS) leads, holding roughly 37% of segment value — the single largest regional share. Functional Electrical Stimulation (FES) is the second-largest contributor. Spinal Cord Stimulation (SCS), Deep Brain Stimulation (DBS), Primary Progressive Multiple Sclerosis (PPMS), Secondary Progressive Multiple Sclerosis (SPMS), Clinically Isolated Syndrome (CIS) and Transcutaneous Electrical Nerve Stimulation (TENS) make up the remainder, in descending order.
- By 2032, Relapsing-remitting Multiple Sclerosis (RRMS) alone is expected to reach USD 41 Million, with Functional Electrical Stimulation (FES) at USD 30 Million.
Market Dynamics
Unlock the Full Data
Get This Chart
Access the complete chart and underlying data to support your research, analysis, and business decisions.
Powering the world's best teams.
From next-gen startups to established enterprises.
Get in Touch
Let's work together
support@wantstats.comSee our work in action
Start your data driven journey with us!
What our clients say
Trusted by forward-thinking businesses
for data-driven intelligence



